ReviewHealth science reports2026
Global Prevalence and Risk Factors of Suicidal Ideation in Multiple Sclerosis: A Systematic Review and Meta-Analysis.
Review in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Suicidal ideation (SI), attempts, and death have been frequently described and investigated in chronic neurological disorders such as Multiple Sclerosis (MS). This systematic review and meta-analysis estimated the global prevalence of SI in patients with MS and demonstrated associated risk factors. This may help the physician to reduce the rate of suicidal attempts and improve public health. Methods: A comprehensive systematic search was performed on PubMed, Scopus, Embase, and Web of Science to find studies that reported the prevalence of SI or its related factors in MS patients. Studies were screened by the title/abstract and then by their full text. Data extraction was performed for relevant studies. A point prevalence with a 95% confidence interval was estimated. Random-effect meta-analysis was conducted to assess the pooled prevalence of SI. Results: From the 1246 total studies that were found, we included 18 final eligible studies for systematic review and 16 studies for meta-analysis. The prevalence of SI in multiple sclerosis patients was estimated at 20% (95% CI [15-25]), based on random-effect meta-analysis. Among the included studies, higher rates of depression and anxiety, lower family and social support, longer duration of illness, and higher levels of disability were related risk factors for SI in patients with MS. Conclusion: Given the higher prevalence of SI in people with MS than in the general population, it should be considered during routine clinical visits and psychological evaluations. Proper counseling, psychological support, and psychiatric interventions may reduce the lifetime risks and help patients overcome their suicidal thoughts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.